CURVE
27.5.2021 19:33:10 CEST | Business Wire | Press release
Curve, the fast-growing financial super app, has closed the largest ever equity raise on Crowdcube, breaking multiple records during the campaign. The raise closed at 1500 BST today, hitting nearly £10m in funding from 11,795 investors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210527005782/en/
In another record, Curve was the fastest ever company on Crowdcube to raise £6m, which it did in just 2 hours 49 minutes after it went live on 25th May. The fundraise has also been Crowdcube’s most popular in 2021 and far outstrips the total of £6m Curve raised during its 2019 crowdfund.
Curve’s latest campaign went live at 0900 BST on Tuesday (25th May) and closed today. The campaign was designed to enable Curve customers and retail investors to follow in the footsteps of some of tech’s leading institutional investors.
More than 4,000 retail investors took part in the first 60 minutes of the crowdfund, smashing Curve’s initial target of £1m within just 10 minutes of the round opening. Over £3.1m was raised within the first 30 minutes of the campaign, with £4m raised after just 56 minutes.
The funds raised this week follow the £132m Curve has raised in cash and capital commitments to-date to support its rapid growth, including the capital secured in the super app’s recent successful Series C, led by IDC Ventures, Fuel Venture Capital and Vulcan Capital.
Curve will use the funds raised by crowdfunding and its recent Series C round to execute its ambitious growth strategy, focussed on its international expansion and product innovation. This strategy includes the rollout of its award-winning Curve OS platform in the US, broadening its European reach, and the forthcoming launch of Curve Credit in the UK, and in Europe. To deliver this, Curve plans to add at least 200 employees to its workforce over the course of 2021.
Shachar Bialick, Founder and CEO of Curve, said: “Ever since our last crowdfund in 2019, our customers have been requesting another opportunity to take a share in Curve. So we launched this campaign to give the public a chance to join us as we embark on the next stage of our exciting journey, when we reveal Curve Credit to the world and launch in the US. We’ve been blown away by the level of interest we’ve seen over the past three days, and I’m so excited to welcome nearly 12,000 investors on board.”
Luke Lang, co-founder and CMO of Crowdcube, says: "Hats off to Curve for another landmark raise with Crowdcube, they continue to impress investors with their unique proposition. It’s a really exciting time for their shareholders, both new and existing, to be part of their ongoing success and their mission to shape the future of finance."
Bobby Aitkenhead, Managing Partner of IDC Ventures, said: “As one of the lead investors in Curve, we’re ecstatic to see such a phenomenal response from its customers and community. Digitalisation is stepping up pace globally, as is financial services fragmentation. Pioneering companies like Curve have huge potential to shape the future of finance. They're already, and will continue, to add so much value to our lives. We’re proud to support them in this journey to the top.”
The crowdfunding round caps a transformational year for Curve. In the last year alone, it has hired over 100 new staff, doubled its customer base, and it has seen the volume of transactions it processes increase by over £1 billion to £2.6 billion, despite the backdrop of a global pandemic.
ENDS
About Curve
Curve is an all in one financial super app. Its mission is to be a one-stop shop for all the financial needs of a consumer; a single point of access to a wide range of financial products and services, bundling together all your money into one smart card and an even smarter app. Unlike other services available in the market today, Curve allows customers to connect and supercharge their legacy banks to the 21st century, without leaving their bank or signing up to a new bank. Curve is live in 31 markets across the UK and European Economic Area (EEA).
Curve provides a host of benefits to its customers:
- Combines a customer’s Mastercard and Visa debit and credit cards in one card.
- Enables customers’ cards to fit into Apple Pay, Google Pay, Samsung Pay, FitBit Pay and many more, even if their banks do not support this integration.
- Curve provides 1% cash back on selected retailers for the first 30 days, or for an unlimited time on Curve’s paid subscriptions.
- With Curve’s patented Go-Back-In-Time® feature, Curve customers may be able to swap their spend to a different account, up to 90 days after the purchase was made.
- Increased security and privacy - Curve simplifies customers’ lives by providing them with only one pin to remember; keeping other sensitive card numbers safe by using Curve when spending online; providing real time spending notifications and the ability to lock the Curve card directly from the app.
- Peace of mind - Curve’s premium Metal offering provides mobile phone insurance and travel insurance to ensure customers can focus on living their lives, rather than worrying about losing their phone or bags when they travel.
Curve supports Mastercard and Visa networks. The Curve Card and e-money, related to cards issued in the UK, is issued by Curve OS Limited, authorised in the UK by the Financial Conduct Authority to issue electronic money (firm reference number 900926). The Curve Card and e-money, related to cards issued in the EEA, is issued by Curve Europe UAB, authorised in Lithuania by the Bank of Lithuania (electronic money institution license No. 73 issued on 22 of October, 2020).
For more information go to www.curve.com , like our Facebook page and follow us on LinkedIn , Twitter @imaginecurve and Instagram @imaginecurve .
END
View source version on businesswire.com: https://www.businesswire.com/news/home/20210527005782/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
